胰腺癌术前胆道引流:塑料与金属支架长期结局的全国倾向评分匹配分析
基于日本全国临床数据库的倾向评分匹配队列研究,纳入2012至2017年间胰腺导管腺癌行胰十二指肠切除术前接受胆道引流的患者,比较塑料支架与金属支架的总生存期和无复发生存期。中位随访63.1个月,两组总生存期和无复发生存期均无显著差异,新辅助治疗亚组及内镜逆行胰胆管造影与经皮肝穿刺胆道引流比较亦无生存差异。支架选择应基于引流时长和治疗策略个体化,而非期望长期预后。
要点
- 胰腺癌术前胆道引流中,塑料支架与金属支架的总生存期和无复发生存期无显著差异。
- 新辅助治疗亚组中两种支架的长期肿瘤学结局同样无显著差异。
- 内镜逆行胰胆管造影与经皮肝穿刺胆道引流的生存结局亦无显著差异。
核心结论
- 在胰腺导管腺癌行胰十二指肠切除术前接受胆道引流的患者中,塑料支架与金属支架在长期肿瘤学及手术结局方面无显著差异,包括接受新辅助治疗的患者。
- 支架选择应基于引流持续时间和治疗策略进行个体化,而非基于对长期预后的期望。
研究设计与样本
- 全国性倾向评分匹配队列研究,使用日本全国临床数据库。
- 纳入2012至2017年间接受术前胆道引流后行胰十二指肠切除术的胰腺导管腺癌患者。
- 6429例合格患者中,5621例接受内镜逆行胰胆管造影(塑料支架n=3225,金属支架n=451,内镜下鼻胆管引流n=1823,排除122例),808例接受经皮肝穿刺胆道引流。
- 主要终点为总生存期,次要终点包括无复发生存期和手术结局。
主要发现
- 匹配后中位随访63.1个月(IQR 38.9-77.6个月),塑料支架与金属支架的总生存期和无复发生存期在整体内镜逆行胰胆管造影队列和新辅助治疗亚组中均无显著差异。
- 两组术后不良事件无显著差异。
- 二次分析显示内镜逆行胰胆管造影与经皮肝穿刺胆道引流之间无生存差异。
临床怎么用
- 胰腺癌术前胆道引流的支架选择可结合预期引流时长和治疗策略个体化决定,不必为追求长期预后而常规选用金属支架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Preoperative biliary drainage (PBD) is frequently required in patients with pancreatic ductal adenocarcinoma (PDAC) undergoing curative intent surgery presenting with obstructive jaundice. With the increasing use of neoadjuvant therapy (NAT), optimal stent selection-plastic stents (PSs) versus metal stents (MSs)-remains controversial, particularly regarding long-term outcomes. Here, using the National Clinical Database, we compared overall survival (OS) and recurrence-free survival (RFS) between MSs and PSs in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) before pancreaticoduodenectomy (PD) for PDAC. METHODS: We performed a nationwide propensity score-matched cohort study of patients with PDAC who underwent PD after PBD between 2012 and 2017. Patients who underwent ERCP were categorized into 2 groups: PS and MS. The primary endpoint was OS; secondary end points included RFS and surgical outcomes. Secondary analyses included a NAT subgroup and comparison of ERCP with percutaneous transhepatic biliary drainage (PTBD). RESULTS: Among 6429 eligible patients, 5621 underwent ERCP (PS: n = 3225; MS: n = 451; endoscopic nasobiliary drainage: n = 1823; excluded cases: n = 122) and 808 underwent PTBD. After matching, with a median follow-up period of 63.1 months (IQR, 38.9-77.6 months), OS and RFS demonstrated no significant differences between PSs and MSs, both in the overall ERCP cohort and the NAT subgroup. Postoperative adverse events did not differ significantly between the groups. Secondary analysis showed no survival differences between ERCP and PTBD. CONCLUSIONS: In this nationwide real-world propensity score-matched study, no significant differences were observed between PSs and MSs in long-term oncologic and surgical outcomes after PD for PDAC, including among patients who received NAT. Stent choice should be individualized based on drainage duration and treatment strategy, rather than expectations of long-term prognosis.
引用
- Nagai K, Hirakawa S, Mizuma M, et al. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Gastrointest Endosc. 2026. PMID: 42248481. doi:10.1016/j.gie.2026.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。